Technology
Health
Biotechnology

MacroGenics

$14.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-2.97%) Today
$0.00 (0.00%) As of 4:28 PM EDT after-hours

Why Robinhood?

You can buy or sell MacroGenics and other stocks, options, ETFs, and crypto commission-free!

About MGNX

MacroGenics, Inc. Common Stock, also called MacroGenics, is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Read More 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Employees
364
Headquarters
Rockville, Maryland
Founded
2000
Market Cap
716.95M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
395.18K
High Today
$15.18
Low Today
$14.67
Open Price
$15.17
Volume
334.86K
52 Week High
$26.39
52 Week Low
$9.87

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical

MGNX Earnings

-$1.34
$0.09
$1.53
$2.96
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.